Namida Lab Partners with Helios Software to Build App for Broadening Clinical Trial Accessibility
FAYETTEVILLE, Ark. And Boston, Mass – Namida Lab®, Inc., a product stage biotech company in Fayetteville with a mission of developing novel cancer diagnostics based on proteins from tears, has partnered with Helios Software, a Boston-based health information technology company, to create a platform, including a consumer app to streamline the onboarding process and increase accessibility and population diversity in clinical trials. The app is free to download and available to participants in clinical trials in both Apple App and Google Play stores under the name “Namida Lab”.
The app developed by Helios Software team is HIPPA compliant and will allow participants to sign up for trials digitally, execute consents, and enter health information all from their phone. Helios Software founder, and chief software architect, Steve Munini is “excited to work with Namida Lab to build out a platform to simplify participation for individuals and inspire new solutions to challenging healthcare issues.”
Helios Software builds software solutions that enable health information exchange both within and between healthcare organizations. They work to build systems and applications that allow information to move more freely and securely by utilizing the new HL7 FHIR standard, which runs on Apache Cassandra – a fault-tolerant, high availability, distributed database for mission critical data.
“The motivation behind development of a mobile application was to simplify the enrollment process for both the participant and the clinical site, reducing the burden on already over-burdened clinical staff. An added benefit has been the ability to not only collaborate with non-traditional clinical settings such as community clinics, but also to make clinical trial enrollment available directly to study participants when clinical collaborations could not be established. Switching from paper-based solutions to the platform developed by Helios has saved our clinical research staff and study participants untold number of hours and have allowed us to offer participation to even more interested individuals”, says Dr. Anna Daily, Vice President of product development and Innovation at Namida Lab.
About Namida Lab
Namida Lab Inc. is an Arkansas-based biotech company specializing in biomarker-based testing to improve diagnostic testing and patient outcomes. Namida’s first product, Melody® is an accurate, inexpensive, and non-invasive test for breast cancer screening available by prescription only. Auria™, a direct-to-consumer short term breast cancer risk assessment test, will be released in 2022. To learn more please visit www.auria.care
Namida was founded in 2019 and has assembled a talented team with experience across diagnostic, medical information, and scientific automation fields to develop a diagnostic platform leveraging the untapped power of tears. Namida operates a high complexity CLIA (Clinical Laboratory Improvement Amendments) certified lab. Its Research & Development Lab works in tandem with the CLIA Lab to develop medical screening and diagnostic tools.
